Pharmaceutical War: Novo Nordisk Sues Eli Lilly Over Misleading Weight Loss Drug Advertisements

Competition between the two largest players in the weight loss and diabetes medication market is escalating in the courtroom. The Danish company Novo Nordisk has filed a complaint against the American Eli Lilly & Co. in a US federal court, accusing its competitor of using misleading advertising campaigns.

According to Novo Nordisk, Eli Lilly's advertisements for the drugs Zepbound (for weight loss) and Mounjaro (for diabetes) use outdated comparative data. The main dispute focuses on the fact that Lilly compares the effects of its products with lower doses of Wegovy (a Novo product), instead of the current, higher doses that are already available on the market.

Essence of the Dispute
Novo claims that Lilly's advertisements imply an advantage that does not exist when directly comparing contemporary therapeutic regimens. Specifically, while Lilly claims that Zepbound users lose an average of 50 pounds, Novo points out that when compared to a higher dose of Wegovy, the difference in results is negligible.

Market Context and Economic Consequences
The battle is being fought for a massive market which, according to Bloomberg Intelligence, is expected to reach $120 billion annually by 2030. Although Novo Nordisk was the first leader with Wegovy, Eli Lilly entered aggressively with Zepbound and is currently a strong competitor in sales.

The market reaction was immediate – Lilly shares fell by 0.6%, while Novo Nordisk shares in Copenhagen reported a decline of 1.6% immediately following the news.

Novo Nordisk is requesting the court to order an immediate halt to the disputed advertisements and the publication of corrective messages. The lawsuit is based on violations of unfair competition and misleading advertising laws (Lanham Act).